Key result
Enhanced activation of JNKs and ERKs occurs in various cardiovascular disease models, suggesting MAPKs may be a useful target for treating cardiovascular hypertrophy and remodeling.
No takes yet. Share an insight, caveat, or question.
Caution against clinical adoption of MAPK inhibitors from models alone; leaves open their role in hypertrophy and remodeling.
Kim et al. (1999) conducted a review in Cardiovascular hypertrophy and remodeling. MAPKs (ERKs and JNKs) activation vs. Normotensive or uninjured models was evaluated on Cardiovascular hypertrophy and remodeling. Enhanced activation of JNKs and ERKs occurs in various cardiovascular disease models, suggesting MAPKs may be a useful target for treating cardiovascular hypertrophy and remodeling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: